Lampalizumab:治療薬市場分析(効能、SWOT、販売予測)

◆英語タイトル:Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
◆発行会社/調査会社:GlobalData
◆商品コード:GDHC488DFR
◆発行日:2014年10月31日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:109
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD3,495 ⇒換算¥384,450見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD6,990 ⇒換算¥768,900見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD10,485 ⇒換算¥1,153,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Lampalizumab:治療薬市場分析(効能、SWOT、販売予測)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Lampalizumab (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023

Summary

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Lampalizumab, also known as anti-factor D (as well as RG7417 by Roche and as FCFD4514S by its subsidiary, Genentech), is an antigen-binding fragment of a humanized mAb that targets complement factor D, the rate-limiting enzyme involved in the activation of the alternative complement pathway.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lampalizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lampalizumab for the top country from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Lampalizumab performance.
- Obtain sales forecast for Lampalizumab from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

*** レポート目次(コンテンツ)***

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Related Reports 12
3 Disease Overview 14
3.1 Macular Degeneration Overview 14
3.1.1 Etiology and Pathophysiology 16
3.1.2 Classification 20
3.1.3 Symptoms and Diagnosis 22
3.2 Macular Edema Overview 25
3.2.1 Etiology and Pathophysiology 26
3.2.2 Classification 29
3.2.3 Symptoms and Diagnosis 30
4 Disease Management 33
4.1 Diagnosis and Treatment Overview 33
4.1.1 Macular Edema Diagnosis 33
4.1.2 Macular Degeneration Diagnosis 33
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 34
4.1.4 Clinical Practice 36
5 Competitive Assessment 50
5.1 Overview 50
6 Unmet Need and Opportunity 52
6.1 Overview 52
6.2 Treatment for Dry AMD 53
6.2.1 Unmet Need 53
6.2.2 Gap Analysis 55
6.2.3 Opportunity 57
6.3 Longer-Acting Anti-VEGF Drug Therapy 59
6.3.1 Unmet Need 59
6.3.2 Gap Analysis 61
6.3.3 Opportunity 61
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 62
6.4.1 Unmet Need 62
6.4.2 Gap Analysis 63
6.4.3 Opportunity 64
6.5 Less Invasive Drug Formulations 64
6.5.1 Unmet Need 64
6.5.2 Gap Analysis 65
6.5.3 Opportunity 66
6.6 Awareness and Earlier Patient Diagnosis 67
6.6.1 Unmet Need 67
6.6.2 Gap Analysis 68
6.6.3 Opportunity 68
6.7 Home Monitoring of AMD Progression 69
6.7.1 Unmet Need 69
6.7.2 Gap Analysis 70
6.7.3 Opportunity 71
7 Pipeline Assessment 73
7.1 Overview 73
7.2 Promising Drugs in Clinical Development 74
8 Lampalizumab 76
8.1 Overview 76
8.2 Efficacy 79
8.3 Safety 80
8.4 Dosing and Formulation 81
8.5 Potential Clinical and Commercial Positioning 81
8.6 SWOT Analysis 82
8.7 Forecast 82
9 Appendix 84
9.1 Bibliography 84
9.2 Abbreviations 98
9.3 Methodology 101
9.4 Forecasting Methodology 101
9.4.1 Diagnosed ME and AMD Patients 102
9.4.2 Percentage of Drug-Treated Patients 102
9.4.3 General Pricing Assumptions 102
9.4.4 Pricing of Pipeline Agents 103
9.5 Primary Research – KOLs Interviewed for this Report 104
9.6 Primary Research – High-Prescribers Survey 105
9.7 About the Authors 106
9.7.1 Analyst 106
9.7.2 Therapy Area Director 106
9.7.3 Global Head of Healthcare 107
9.8 About GlobalData 108
9.9 Disclaimer 108

1.1 List of Tables
Table 1: ARM System Classification of AMD 21
Table 2: Symptoms of AMD 22
Table 3: National and International Treatment Guidelines for ME and AMD 35
Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 36
Table 5: Leading Treatments for ME and AMD, 2014 51
Table 6: Unmet Needs and Opportunities in ME and AMD 53
Table 7: Promising Drugs in Clinical Development for ME and AMD 74
Table 8: Comparison of Drugs in Development for ME and AMD, 2014 74
Table 9: Product Profile - Lampalizumab 79
Table 10: SWOT Analysis - Lampalizumab, 2014 82
Table 11: Global Sales Forecast ($m) for lampalizumab, 2013-2023 83
Table 12: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 105

1.2 List of Figures
Figure 1: Anatomy of the Eye and Macula 14
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD 23
Figure 3: Color Fundus Photographs of Dry and Wet AMD 23
Figure 4: FAF Imaging of GA 24
Figure 5: Imaging of wAMD 25
Figure 6: CMT in DME 31
Figure 7: RVOs (BRVO and CRVO) on an FA 31
Figure 8: Increased CRT in ME-RVO 32
Figure 9: ME Clinical Treatment Flowchart 42
Figure 10: AMD Clinical Treatment Flowchart 49
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023 75
Figure 12: Lampalizumab’s Development in wAMD 79
Figure 13: Clinical and Commercial Positioning of lampalizumab 81

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※H&Iグローバルリサーチは調査サービスを通じて、お客様の海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをご提供しております。
※当市場調査資料"Lampalizumab:治療薬市場分析(効能、SWOT、販売予測)"は"GlobalData社"が調査・発行しており、H&Iグローバルリサーチが販売します。お気軽にお問い合わせください。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。